Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-11-15 DOI:10.1080/14737140.2023.2280643

Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li

{"title":"Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis.","authors":"Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li","doi":"10.1080/14737140.2023.2280643","DOIUrl":null,"url":null,"abstract":"Objectives: This meta-analysis aimed to evaluate the prognostic significance of circulating long non-coding RNAs (lncRNAs) in colorectal cancer (CRC).Methods: A comprehensive literature search was conducted in databases (Embase, Web of Science, PubMed, and Cochrane Library) up to July 2022. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed with Review Manager 5.4 and Stata 17.0. Publication bias was assessed using Begg's test, and sensitivity analysis was conducted to validate the meta-analysis results.Results: Ten articles, comprising 1,473 CRC patients and 18 different circulating lncRNAs, were included. Thirteen circulating lncRNAs were found to be up-regulated in CRC patients, while five were down-regulated. High expression of circulating lncRNAs up-regulated in CRC patients was associated with shorter CRC OS (HR = 2.91, 95% CI: 1.17, 7.22; P = 0.02, I2 = 86%). Conversely, high expression of circulating lncRNAs down-regulated in CRC patients was linked to longer CRC OS (HR = 0.16, 95% CI: 0.07, 0.40; P < 0.0001, I2 = 0%) and improved DFS (HR = 0.52, 95% CI: 0.37, 0.74; P = 0.0002, I2 = 0%). Additionally, circulating lncRNA levels correlated with TNM staging, tumor location, and lymph node metastasis.Conclusion: Circulating lncRNAs show promise as prognostic markers for CRC patients, but further studies are warranted to validate these findings.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2280643","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This meta-analysis aimed to evaluate the prognostic significance of circulating long non-coding RNAs (lncRNAs) in colorectal cancer (CRC).

Methods: A comprehensive literature search was conducted in databases (Embase, Web of Science, PubMed, and Cochrane Library) up to July 2022. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed with Review Manager 5.4 and Stata 17.0. Publication bias was assessed using Begg's test, and sensitivity analysis was conducted to validate the meta-analysis results.

Results: Ten articles, comprising 1,473 CRC patients and 18 different circulating lncRNAs, were included. Thirteen circulating lncRNAs were found to be up-regulated in CRC patients, while five were down-regulated. High expression of circulating lncRNAs up-regulated in CRC patients was associated with shorter CRC OS (HR = 2.91, 95% CI: 1.17, 7.22; P = 0.02, I2 = 86%). Conversely, high expression of circulating lncRNAs down-regulated in CRC patients was linked to longer CRC OS (HR = 0.16, 95% CI: 0.07, 0.40; P < 0.0001, I2 = 0%) and improved DFS (HR = 0.52, 95% CI: 0.37, 0.74; P = 0.0002, I2 = 0%). Additionally, circulating lncRNA levels correlated with TNM staging, tumor location, and lymph node metastasis.

Conclusion: Circulating lncRNAs show promise as prognostic markers for CRC patients, but further studies are warranted to validate these findings.

查看原文本刊更多论文

循环长非编码RNA对结直肠癌癌症患者的预后价值：一项荟萃分析。

目的：本荟萃分析旨在评估循环长非编码RNA（lncRNA）在癌症（CRC）中的预后意义，重点探讨其与无病生存期（DFS）、总生存期（OS）和临床病理特征的关系。方法：截至2022年7月，在数据库（Embase、Web of Science、PubMed和Cochrane Library）中进行全面的文献检索，以确定研究循环lncRNA在CRC中的预后价值的研究。纳入研究的质量采用纽卡斯尔-渥太华量表（NOS）进行评估。使用Review Manager 5.4和Stata 17.0进行统计分析。使用Begg检验评估发表偏倚，并进行敏感性分析以验证荟萃分析结果。结果：纳入10篇文章，包括1473名CRC患者和18种不同的循环lncRNA。CRC患者中发现13个循环lncRNA上调，而5个下调。循环lncRNA在CRC患者中的高表达上调与较短的CRC OS相关（HR = 2.91.95%CI:1.177.22；P = 0.02，I2 = 86%）。相反，CRC患者循环lncRNA的高表达下调与较长的CRC OS有关（HR = 0.16,95%CI:0.07,0.40；P P = 0.0002，I2 = 0%）。此外，循环lncRNA水平与TNM分期、肿瘤位置和淋巴结转移相关。结论：循环lncRNA有望作为CRC患者的预后标志物。然而，鉴于本研究中包含的文章数量和代表性有限，有必要进行进一步的研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.